ATRC
AtriCure, Inc.
$26.92
-0.66%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (81%)
Inst. Holders9 funds
Inst. Value$303.3M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 3S
Insider Net $-$375.8K
SEC Reports3
Congressional1 trades
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001323885·Prev Close $27.10
Recent Activity
May 22, 2026
SEC
Two AtriCure insiders sold a total of $227K in open-market sales over a 7-day window, representing 0.015% of the $1.5B m
CLUSTER — Impact 2/10
May 20, 2026
Insider
Prange Karen sold 3,000 shares
Director @ $28.65 ($86.0K)
May 18, 2026
Insider
JOHNSON B KRISTINE sold 6,144 shares
Director @ $0.00 ($0.00)
May 18, 2026
Insider
WHITE ROBERT S. sold 6,144 shares
Director @ $0.00 ($0.00)
May 5, 2026
SEC
AtriCure reported Q1 2026 revenue of $141.2M (+14.3% YoY) and achieved GAAP net income of $0.1M, beating EPS consensus o
8-K — Impact 6/10
Apr 6, 2026
SEC
AtriCure, Inc. filed a definitive proxy statement (DEFA14A) for its 2026 annual meeting, which is a routine regulatory f
DEFA14A — Impact 3/10
Inst.
MORGAN STANLEY — ADD
346,116 shares ($13.7M)
Inst.
FMR LLC — TRIM
285,759 shares ($11.3M)
Price Targets
$47.00
+72.2% upside
Strong Buy
Current $27.30
Low $36.00
Median $47.50
High $55.00
8 analysts
$36.00
$55.00
Analyst Ratings
4Strong Buy
9Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Feb 18, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Feb 18, 2026 | UBS | MAINTAIN | Buy → Buy |
| Feb 18, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Feb 18, 2026 | Oppenheimer | DOWNGRADE | Outperform → Perform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.02 ▼ -31.0% | $-0.06 — $0.08 | 220% YoY | 8 |
| Next Q | $0.02 ▼ -68.0% | $-0.03 — $0.04 | 253% YoY | 8 |
| Current FY | $0.12 ▼ -12.9% | $0.04 — $0.16 | 211% YoY | 8 |
| Next FY | $0.35 ▼ -5.7% | $0.24 — $0.59 | 186% YoY | 8 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two AtriCure insiders sold a total of $227K in open-market sales over a 7-day window, representing 0.015% of the $1.5B m
May 22, 2026
MIXED
8-K
6/10
AtriCure reported Q1 2026 revenue of $141.2M (+14.3% YoY) and achieved GAAP net income of $0.1M, beating EPS consensus o
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $194.0M | — |
| BANK OF AMERICA CORP | $26.7M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $17.3M | NEW |
| TWO SIGMA INVESTMENTS, LP | $15.1M | TRIM |
| MORGAN STANLEY | $13.7M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Prange Karen | SELL | $86.0K |
| May 18, 2026 | JOHNSON B | A | $0.00 |
| May 18, 2026 | WHITE ROBERT | A | $0.00 |
| May 18, 2026 | GROVES REGINA | A | $0.00 |
| May 18, 2026 | WEHRWEIN SVEN | A | $0.00 |
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
9 institutional holders with $303.3M total value (7,667,145 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, CHARLES. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,903,755 | $194.0M | 64.0% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 675,731 | $26.7M | 8.8% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 437,883 | $17.3M | 5.7% | NEW |
| 4 | TWO SIGMA INVESTMENTS, LP | 380,499 | $15.1M | 5.0% | TRIM -38.3% |
| 5 | MORGAN STANLEY | 346,116 | $13.7M | 4.5% | ADD +83.3% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 321,900 | $12.7M | 4.2% | TRIM -31.5% |
| 7 | FMR LLC | 285,759 | $11.3M | 3.7% | TRIM -27.5% |
| 8 | NORGES BANK | 214,016 | $8.5M | 2.8% | NEW |
| 9 | WELLS FARGO & COMPANY/MN | 101,486 | $4.0M | 1.3% | TRIM -35.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 188,816 | 346,116 | +83.3% | $13.7M | 2025-Q4 |
| FMR LLC | TRIM | 393,996 | 285,759 | -27.5% | $11.3M | 2025-Q4 |
| NORGES BANK | NEW | — | 214,016 | — | $8.5M | 2025-Q4 |
| FMR LLC | ADD | 270,285 | 393,996 | +45.8% | $13.9M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 377,700 | 258,800 | -31.5% | $9.1M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 252,090 | 188,816 | -25.1% | $6.7M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 127,602 | 81,973 | -35.8% | $2.9M | 2025-Q3 |
| NORGES BANK | EXIT | 10,438 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 667,925 | 411,913 | -38.3% | $13.5M | 2025-Q2 |
| FMR LLC | TRIM | 992,958 | 270,285 | -72.8% | $8.9M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 386,944 | 252,090 | -34.9% | $8.3M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 70,809 | 127,602 | +80.2% | $4.2M | 2025-Q2 |
| NORGES BANK | NEW | — | 10,438 | — | $342.1K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 163,900 | 307,900 | +87.9% | $9.9M | 2025-Q1 |
| UBS Group AG | TRIM | 144,180 | 103,027 | -28.5% | $3.3M | 2025-Q1 |
| NORGES BANK | EXIT | 111,947 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 98,100 | 163,900 | +67.1% | $5.0M | 2024-Q4 |
| UBS Group AG | DOUBLED | 44,545 | 144,180 | +223.7% | $4.4M | 2024-Q4 |
| NORGES BANK | TRIM | 158,444 | 111,947 | -29.3% | $3.4M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 95,281 | 57,407 | -39.7% | $1.8M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 394,584 | — | $11.1M | 2024-Q3 |
14 unique insiders with 3 transactions. Net insider value: -$375.8K ($0.00 bought, $375.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Prange Karen | Director | SELL | 3,000 | $28.65 | $86.0K |
| May 18, 2026 | JOHNSON B KRISTINE | Director | A | 6,144 | $0.00 | $0.00 |
| May 18, 2026 | WHITE ROBERT S. | Director | A | 6,144 | $0.00 | $0.00 |
| May 18, 2026 | GROVES REGINA E | Director | A | 6,144 | $0.00 | $0.00 |
| May 18, 2026 | WEHRWEIN SVEN | Director | A | 6,144 | $0.00 | $0.00 |
| May 18, 2026 | Nachman Shlomo | Director | A | 6,144 | $0.00 | $0.00 |
| May 18, 2026 | Yuen Maggie | Director | A | 6,144 | $0.00 | $0.00 |
| May 18, 2026 | Telman Deborah H | Director | A | 6,144 | $0.00 | $0.00 |
| May 18, 2026 | Prange Karen | Director | A | 6,144 | $0.00 | $0.00 |
| May 15, 2026 | Doraiswamy Vinayak | Chief Scientific Officer | SELL | 5,000 | $28.13 | $140.7K |
| Mar 12, 2026 | Doraiswamy Vinayak | Chief Scientific Officer | SELL | 5,000 | $29.83 | $149.2K |
| Mar 10, 2026 | WHITE ROBERT S. | Director | M | 10,000 | $14.99 | $149.9K |
| Mar 10, 2026 | WHITE ROBERT S. | Director | M | 10,000 | $14.99 | $149.9K |
| Mar 6, 2026 | CARREL MICHAEL H | President, CEO, & Director | G | 5,000 | $0.00 | $0.00 |
| Mar 1, 2026 | CARREL MICHAEL H | President, CEO, & Director | F | 72,777 | $31.26 | $2.3M |
| Mar 1, 2026 | Noznesky Justin J | Chief Mktg & Strategy Officer | A | 27,991 | $0.00 | $0.00 |
| Mar 1, 2026 | Noznesky Justin J | Chief Mktg & Strategy Officer | F | 15,586 | $31.26 | $487.2K |
| Mar 1, 2026 | Doraiswamy Vinayak | Chief Scientific Officer | A | 30,390 | $0.00 | $0.00 |
| Mar 1, 2026 | Doraiswamy Vinayak | Chief Scientific Officer | F | 15,585 | $31.26 | $487.2K |
| Mar 1, 2026 | Wirick Angela L | Chief Financial Officer | A | 39,987 | $0.00 | $0.00 |
| Mar 1, 2026 | Wirick Angela L | Chief Financial Officer | F | 22,965 | $31.26 | $717.9K |
| Mar 1, 2026 | Privitera Salvatore | Chief Technical Officer | A | 30,390 | $0.00 | $0.00 |
| Mar 1, 2026 | Privitera Salvatore | Chief Technical Officer | F | 13,127 | $31.26 | $410.4K |
| Mar 1, 2026 | CARREL MICHAEL H | President, CEO, & Director | A | 68,618 | $0.00 | $0.00 |
| Mar 1, 2026 | Dahlquist Karl S. | Chief Legal Officer | A | 27,991 | $0.00 | $0.00 |
| Mar 1, 2026 | Dahlquist Karl S. | Chief Legal Officer | F | 15,687 | $31.26 | $490.4K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.7/10.
NEUTRAL
CLUSTER
2/10
Two AtriCure insiders sold a total of $227K in open-market sales over a 7-day window, representing 0
May 22, 2026
MIXED
8-K
6/10
AtriCure reported Q1 2026 revenue of $141.2M (+14.3% YoY) and achieved GAAP net income of $0.1M, bea
May 5, 2026
NEUTRAL
DEFA14A
3/10
AtriCure, Inc. filed a definitive proxy statement (DEFA14A) for its 2026 annual meeting, which is a
Apr 6, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (81% buy). Based on 16 analysts: 4 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$47.00 mean target
+72.2% upside
Strong Buy (3.00)
$36.00 Low
$55.00 High
| Metric | Value |
|---|---|
| Current Price | $27.30 |
| Target Low | $36.00 |
| Target Mean | $47.00 |
| Target Median | $47.50 |
| Target High | $55.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.02 | $-0.06 | $0.08 | 219.9% | -31.0% | 1↑ 1↓ | $0.2B | 11.5% | 8 |
| Next Q 2026-09-30 |
$0.02 | $-0.03 | $0.04 | 253.1% | -68.0% | — | $0.2B | 12.6% | 8 |
| Current FY 2026-12-31 |
$0.12 | $0.04 | $0.16 | 210.8% | -12.9% | 1↑ 1↓ | $0.6B | 13.2% | 8 |
| Next FY 2027-12-31 |
$0.35 | $0.24 | $0.59 | 186.1% | -5.7% | 0↑ 1↓ | $0.7B | 12.1% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.024 | |
| 7d ago | $0.008 | +0.016 |
| 30d ago | $0.035 | -0.011 |
| 60d ago | $0.035 | -0.011 |
| 90d ago | $-0.021 | +0.045 |
7 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | UBS | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 18, 2026 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Feb 18, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 12, 2026 | Needham | REITERATE | Buy | Buy |
| Dec 16, 2025 | JP Morgan | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 3 | 0 | 0 | 81% | |
| May 1, 2026 | 4 | 9 | 3 | 0 | 0 | 81% | |
| Apr 1, 2026 | 4 | 8 | 3 | 0 | 0 | 80% | |
| Mar 1, 2026 | 4 | 8 | 3 | 0 | 0 | 80% | |
| Feb 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | AtriCure Inc | Apr 8, 2026 (37d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 5, 2026
short_volume
Short Volume: ATRC — 85.2% short (0.5M / 0.6M)
Short: 486,651 | Exempt: 0 | TRF Vol: 571,190 | Short Ratio: 85.2% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
ATRC Q1 2026 Earnings After Market Close — 2026-05-05
May 4, 2026
short_volume
Short Volume: ATRC — 85.4% short (0.6M / 0.7M)
Short: 593,711 | Exempt: 0 | TRF Vol: 695,102 | Short Ratio: 85.4% | Off-exchange volume (dark pool + OTC)